Fishawack Health is a UK-headquartered global healthcare communications agency.

Investment type
  • Management buyout
Deal value


Exit type
  • Private equity sale
Exit date

March 2020

Quote mark

Our goal is to increase the range of healthcare communications services that we can offer to commercial and medical affairs teams internationally, and with the financial and strategic support of the team at LDC we have been able to do just that.”

Oliver Dennis, Co-founder & CEO
Fishawack Health

We exited our investment in Fishawack Heath in March 2020 to investment firm Bridgepoint for an undisclosed sum.

A strong heritage in buy & build and healthcare

LDC plays an active role in supporting the buy and build strategies of its portfolio companies, enabling them to drive growth and market share. Between July 2018 and March 2020, LDC-backed businesses across the UK acquired 40 companies with a total enterprise value of over £220m.

LDC has a successful track record in backing the management teams of healthcare businesses, having invested almost £300m in more than 35 healthcare firms. Fishawack joins a long list of successful partnerships including Quantum Pharmaceutical which went through an IPO in 2014, pharmaceutical manufacturer Penn Pharma and leading clinical trials business Synexus. More recently, LDC invested in Ashtons Pharmacy Services.